Moderna's Betting on Bird Flu Before It Bets on Us
Moderna launched a 4,000-person Phase 3 trial for its mRNA bird flu vaccine, and interim data already show 82.7% efficacy against H5N1. With avian flu infecting over 1,000 dairy herds and jumping into dozens of mammal species, this is pandemic prep before the pandemic.
The Vaccine for a Pandemic That Hasn't Happened Yet
Most vaccine trials chase a disease that's already spreading. Moderna just flipped the script.
The company launched a Phase 3 trial of its mRNA bird flu vaccine in the U.S. and U.K., targeting H5N1 avian influenza. That's the strain that's been tearing through poultry farms, infecting dairy cattle in 17 U.S. states, and popping up in everything from seals to mountain lions. The twist? There's no human pandemic. Not yet, anyway.
This is pandemic prep on hard mode: build the fire extinguisher before the house catches fire. And the early data suggest Moderna might actually have a good one.
What We're Dealing With
Bird flu has been busy. H5N1 has infected nearly 970 dairy herds across the U.S. since it first jumped to cows in early 2024. It's shown up in wild mammals across North America and Europe, from foxes and otters to bears and bottlenose dolphins. For the first time ever, a sheep in the U.K. tested positive.
Human cases remain rare and sporadic: about 75 infections across the Americas since 2022, with two deaths. None have involved sustained person-to-person spread. The CDC still rates the risk to the general public as low.
But here's what keeps epidemiologists up at night. Every time H5N1 jumps into a mammal, it gets another lottery ticket. Another shot at mutating into something that spreads between people as easily as the common cold. The virus hasn't won that lottery yet, but it's buying a lot of tickets.
Inside the Trial
Moderna's candidate, called mRNA-1018, uses the same lipid nanoparticle technology that powered its COVID vaccines. Think of it as a set of genetic instructions wrapped in a tiny fat bubble, teaching your immune system to recognize H5N1's signature protein before the real thing ever shows up.
The Phase 3 trial plans to enroll roughly 4,000 healthy adults across 38 sites. About three-quarters of participants will be in the U.K., with the rest in the U.S. Moderna is prioritizing older adults and poultry workers, the people most likely to encounter the virus. Participants get , then researchers track their antibody responses and safety data for about seven months.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
two shots
Because H5N1 isn't circulating widely in humans, the trial can't measure efficacy the traditional way (counting who gets sick). Instead, it relies on immunogenicity, essentially measuring whether the vaccine generates enough antibodies to cross the protective threshold. It's a standard approach for pandemic flu vaccines; you prove the immune response works, then trust the biology.
The whole effort is backed by CEPI (the Coalition for Epidemic Preparedness Innovations), which committed up to $54.3 million to push mRNA-1018 through pivotal testing and toward licensure.
The Early Data Are Turning Heads
Moderna didn't walk into Phase 3 blind. Its Phase 1/2 trial tested the vaccine in about 300 adults, and the numbers were striking.
At baseline, only 2.1% of participants had protective antibody levels against H5N1. Almost nobody had natural immunity; this virus is essentially foreign to the human immune system. After two doses, that number jumped to 97.8%. Antibody levels rose roughly 44-fold from where they started.
Six months later, 70.6% of participants still had protective antibody levels. Side effects were mostly mild: sore arms, fatigue, low-grade fevers. One serious adverse event (a fainting episode) was reported. No signals of myocarditis or pericarditis, the rare heart inflammation that drew scrutiny during COVID vaccine rollouts.
An interim look at Phase 3 data told an even more compelling story. Among the first 142 confirmed H5N1 cases in the trial, only 17 were in the vaccine group versus 125 in the placebo group. That works out to roughly 82.7% efficacy against symptomatic infection. For context, that's better than most seasonal flu shots manage against their targets in a good year.
The Competition Is Real (and Already Stockpiled)
Moderna isn't the only player in bird flu vaccines. It's arguably the flashiest, but governments have been quietly stockpiling older H5N1 vaccines for years.
The U.S. Strategic National Stockpile already holds three FDA-approved H5N1 vaccines from CSL Seqirus, Sanofi, and GSK. In late 2024, BARDA handed out contracts totaling over $70 million to those three manufacturers, with a goal of pushing the stockpile past 10 million doses.
CSL Seqirus has the most deployment-ready position, with cell-based and egg-based vaccines already procured by the U.S., EU, U.K., and Canada. The U.K. alone bought 5 million doses from CSL Seqirus in December 2024. GSK and Sanofi contribute both antigen and adjuvant components to various national stockpiles.
So why does Moderna's entry matter? Speed. Traditional egg-based flu vaccines take months to reformulate when a virus mutates. Moderna claims its mRNA platform can update the vaccine sequence and start manufacturing within about 60 days. In a fast-moving pandemic, that difference could be enormous.
Other mRNA and self-amplifying RNA competitors are earlier in development. Arcturus Therapeutics snagged FDA fast-track designation for its H5N1 candidate in April 2025, but it's still in Phase 1. GSK and CureVac have a joint mRNA H5N1 program in Phase 1/2. Moderna's Phase 3 puts it well ahead of the mRNA pack.
The Bigger Picture: Building the Pandemic Playbook
This trial is really a proof of concept for something larger. Moderna has committed to advancing vaccines against at least 15 priority pathogens (think Nipah, Zika, pandemic flu subtypes) into clinical testing, building what amounts to a vaccine library for future outbreaks. The U.S. government is backing that vision with roughly $590 million in HHS funding for pandemic influenza mRNA programs alone.
As part of the CEPI deal, Moderna has pledged to reserve 20% of its H5 manufacturing capacity for low- and middle-income countries at affordable prices if the vaccine gets licensed. It's a deliberate attempt to avoid the "rich countries first" dynamic that defined early COVID vaccine distribution.
Moderna has already begun rolling submissions to both the FDA and the U.K.'s MHRA, with plans to file a full application by Q3 2026. A complete Phase 3 readout is expected in early 2027.
What It All Means
For investors, mRNA-1018 is less a revenue engine and more an insurance policy. If H5N1 never becomes a human pandemic, the vaccine serves a niche market: government stockpiles, farm workers, first responders. If the virus does make the jump to efficient human spread, Moderna could be sitting on one of the most important medical products in the world.
For the rest of us, the calculus is simpler. The best time to prepare for a pandemic is before it starts. Moderna is placing a very expensive, very public bet that the world learned that lesson from COVID.
Whether H5N1 ever tests that bet is up to the virus.
Deals & M&A5 min read
The $929M Bet on a Drug That Already Failed Twice
Zymeworks is spending $929 million to buy Theravance Biopharma, a company whose lead drug failed twice in late-stage trials. The real prize isn't the drug; it's a portfolio of royalty cash flows that reveals where biotech M&A is really headed.
